首页 › 基金 › BAKER BROS. ADVISORS LP › GLUE
BAKER BROS. ADVISORS LP 对 GLUE 的持仓历史
MONTE ROSA THERAPEUTICS INC · 医疗保健
BAKER BROS. ADVISORS LP 在 Q3 2026 的 13F 申报中披露持有 GLUE(MONTE ROSA THERAPEUTICS INC)4,345,736 股,市值约 US$51.8M,约占其申报组合的 0.25%,在其申报持仓中市值排名第 28 位。 BAKER BROS. ADVISORS LP 最近 13 个申报季度中有 13 个季度披露了 GLUE 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
BAKER BROS. ADVISORS LP 对 GLUE 的持仓演变
BAKER BROS. ADVISORS LP 于 Q3 2023 首次披露 GLUE 持仓:4,916,095 股(约 US$23.5M)。 该持仓在 Q2 2026 达到峰值 4,345,736 股,市值约 US$105.2M。 在 13 次申报中,BAKER BROS. ADVISORS LP 0 次增持、1 次减持、11 次保持不变。 最近一期申报(Q3 2026)显示持股 4,345,736 股、市值约 US$51.8M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 4.92M | $23.55M | 新进 |
| Q4 2023 | 4.92M | $27.78M | 持有 |
| Q1 2024 | 4.92M | $34.66M | 持有 |
| Q2 2024 | 4.92M | $18.39M | 持有 |
| Q3 2024 | 4.92M | $26.06M | 持有 |
| Q4 2024 | 4.92M | $34.12M | 持有 |
| Q1 2025 | 4.92M | $22.81M | 持有 |
| Q2 2025 | 4.92M | $22.17M | 持有 |
| Q3 2025 | 4.92M | $36.43M | 持有 |
| Q4 2025 | 4.35M | $68.14M | 减持 |
| Q1 2026 | 4.35M | $71.49M | 持有 |
| Q2 2026 | 4.35M | $105.17M | 持有 |
| Q3 2026 | 4.35M | $51.84M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 GLUE 与 13F 数据
GLUE(MONTE ROSA THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 48 只申报持有 GLUE,申报仓位最大的包括:Vestal Point Capital, LP (US$85.1M), NEA Management Company, LLC (US$79.8M), BVF INC/IL (US$51.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 GLUE 的基金
- Vestal Point Capital, LP 7.13M 股 · $85.06M · Q3 2026
- NEA Management Company, LLC 6.69M 股 · $79.84M · Q3 2026
- BVF INC/IL 4.28M 股 · $51.02M · Q3 2026
- TCG Crossover Management, LLC 3.78M 股 · $45.11M · Q3 2026
- Versant Venture Management, LLC 3.18M 股 · $37.95M · Q3 2026
- MONTANOVA CAPITAL, LLC 2.92M 股 · $34.79M · Q3 2026
- BRAIDWELL LP 2.53M 股 · $30.14M · Q3 2026
- Aisling Capital Management LP 1.56M 股 · $18.56M · Q3 2026
- Opaleye Management Inc. 745.00K 股 · $18.03M · Q2 2026
- MPM BioImpact LLC 1.13M 股 · $13.42M · Q3 2026
- ADAR1 Capital Management, LLC 1.01M 股 · $12.02M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.00M 股 · $11.93M · Q3 2026
更多关于 BAKER BROS. ADVISORS LP
常见问题
How long has BAKER BROS. ADVISORS LP held GLUE?
BAKER BROS. ADVISORS LP has disclosed GLUE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in GLUE?
As of Q3 2026, BAKER BROS. ADVISORS LP holds 4.35M shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $51.84M, representing 0.25% of its reported portfolio and ranking #28.
Has BAKER BROS. ADVISORS LP been buying or selling GLUE?
In the latest 13F filing (Q3 2026), BAKER BROS. ADVISORS LP held unchanged its position in GLUE. The position peaked in Q2 2026 at 4.35M shares.
Which other funds hold GLUE?
Other major institutional holders of GLUE include Vestal Point Capital, LP, NEA Management Company, LLC, BVF INC/IL, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.